Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):** Initiate at 5 mg twice daily. Increase dose by 5-10 mg every week based on clinical response and tolerability, to a maximum daily dose of 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **Ages 2 to <10 years:** Initiate at 5 mg once daily. Increase dose by 2.5-5 mg every week based on clinical response and tolerability, to a maximum daily dose of 10 mg twice daily (20 mg/day).
* **Ages 10 years and older:** Initiate at 5 mg twice daily. Increase dose by 5-10 mg every week based on clinical response and tolerability, to a maximum daily dose of 10 mg twice daily (20 mg/day).
* **Note:** Dosing for children younger than 2 years is not well-established and should be used with extreme caution.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited, but dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Data is limited.
* **Concomitant Use with CYP2C19 Inhibitors:** Consider reducing clobazam dose.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
**Common:** Somnolence, decreased appetite, constipation, aggression, irritability, fatigue, rash.
**Serious:** Suicidal behavior and ideation, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, physical and psychological dependence, withdrawal symptoms, paradoxical reactions (e.g., increased seizure frequency, agitation).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depressant effects, potentially leading to profound sedation, respiratory depression, coma, and death.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam plasma concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam plasma concentrations.
* **Other Anticonvulsants:** Monitor for potential changes in efficacy or adverse effects of either agent.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of dependence/withdrawal.
* Monitor for suicidal behavior and ideation.
* Monitor for rash and signs of severe skin reactions.
* Consider monitoring clobazam and N-desmethylclobazam (active metabolite) levels, particularly in cases of poor response or increased adverse effects, or when co-administered with drugs affecting CYP2C19.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Withdrawal symptoms can occur upon abrupt discontinuation. Tapering is recommended.
* Rash can be a sign of serious dermatologic reactions; discontinue immediately if suspected.
* The active metabolite, N-desmethylclobazam, has a longer half-life and contributes significantly to the drug's effects.
* Dosing adjustments may be needed when initiating or discontinuing concomitant CYP2C19 inhibitors or inducers.
---
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete details before making any clinical decisions. Dosing may vary based on individual patient factors and local protocols.*
